Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
Public ClinicalTrials.gov record NCT05087056. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb, Randomized, Observer-Blind Study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups.
Study identification
- NCT ID
- NCT05087056
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 305 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 11 Years to 14 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 18, 2021 (Actual)
- Primary completion
- Mar 10, 2027 (Estimated)
- Completion
- Mar 10, 2027 (Estimated)
- Last update posted
- Sep 28, 2026
2021 – 2027
United States locations
- U.S. sites
- 24
- U.S. states
- 18
- U.S. cities
- 22
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35205 | — |
| GSK Investigational Site | Tucson | Arizona | 85745-2696 | — |
| GSK Investigational Site | Ventura | California | 93003 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20016 | — |
| GSK Investigational Site | Miami | Florida | 33156-7397 | — |
| GSK Investigational Site | Miami | Florida | 33173 | — |
| GSK Investigational Site | Macon | Georgia | 31210 | — |
| GSK Investigational Site | Valparaiso | Indiana | 84088 | — |
| GSK Investigational Site | Nicholasville | Kentucky | 40517 | — |
| GSK Investigational Site | Haughton | Louisiana | 71037 | — |
| GSK Investigational Site | Missoula | Montana | 59804 | — |
| GSK Investigational Site | Missoula | Montana | 80216 | — |
| GSK Investigational Site | Grand Island | Nebraska | 68803 | — |
| GSK Investigational Site | Lincoln | Nebraska | 68510 | — |
| GSK Investigational Site | Omaha | Nebraska | 68134 | — |
| GSK Investigational Site | Binghamton | New York | 13905-1118 | — |
| GSK Investigational Site | Endwell | New York | 13850 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28226 | — |
| GSK Investigational Site | Gresham | Oregon | 97030 | — |
| GSK Investigational Site | Charleston | South Carolina | 29414-5834 | — |
| GSK Investigational Site | Kingsport | Tennessee | 37660 | — |
| GSK Investigational Site | Austin | Texas | 75024 | — |
| GSK Investigational Site | Galveston | Texas | 77555 1115 | — |
| GSK Investigational Site | Layton | Utah | 84037 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05087056, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05087056 live on ClinicalTrials.gov.